The test runs on the firm's m2000 PCR platform and is the first on the market to assess resistance to both rifampin and isoniazid.
The investment firm has added the three companies to its US Life Science Tools & Diagnostics coverage while upping Hologic to an Equal Weight rating.
The Scottish firm's product pipeline includes an identification test for bacterial gastroenteritis and genes for Carbapenem resistance.
Six out of 61 miRNAs in a prospective cardiovascular disease study could be reliably measured from plasma samples after more than a dozen years in liquid nitrogen.
The firm says a direct presence in China will help it expand its reach into a market where it has already sold 60 MassArray systems.
This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.
Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.
Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.
A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.